Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-04-02

Clinical Trial Update: 18F-Floretyrosine Expanded Access Program

View source ↗

Summary

Expanded access program for the PET imaging tracer 18F-Floretyrosine is currently available for glioma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 18F-Floretyrosine

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Conditions: Glioma (Any Grade) in the Brain | Status: AVAILABLE